BCL2 and lymphoma: Among these BH3 mimetic compounds, venetoclax (VCX) received accelerated USA FDA approval for the treatment of acute lymphocytic leukemia in 2016 and chronic lymphocytic leukemia and lymphoma in 2019.8 VCX is a potent, selective, and orally available BH3 mimetic that serves as a BCL-2 inhibitor.